Literature DB >> 18305179

The clinical significance of antinucleolar antibodies.

S Khan1, A Alvi, S Holding, M L Kemp, D Raine, P C Doré, W A C Sewell.   

Abstract

BACKGROUND: The importance of antinucleolar antibodies seen by indirect immunofluorescence on HEp-2 cells, although associated with systemic sclerosis (SSc), in unselected patients is unknown. AIMS: To determine the true clinical significance of antinucleolar antibodies in an unselected patient population.
METHODS: Antinucleolar antibody (ANoA) positive samples were identified in the immunology laboratory during routine autoimmune screening tests; case notes were reviewed using a standard proforma.
RESULTS: 104 patients with ANoA were identified and ANoA+ samples were subclassified into homogeneous, clumpy and speckled antinucleolar types. SSc was evident in only two (1.8%) patients. Other connective tissue diseases were identified in 33 patients (32%); 22 patients (21%) had evidence of various malignancies. Both disordered liver function and anaemia were seen in 22 patients and were the commonest laboratory abnormalities.
CONCLUSIONS: Neither the presence nor subtype of ANoA is specific for systemic sclerosis. Laboratory comments appended to results should reflect this fact.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305179     DOI: 10.1136/jcp.2007.049692

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  2 in total

Review 1.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

2.  Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern.

Authors:  Alessandra Dellavance; Cristiane Gallindo; Mariana Guanaes Soares; Neusa Pereira da Silva; Renato Arruda Mortara; Luís Eduardo Coelho Andrade
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.